Individualised and Time-Dependent Prediction of Recurrence After Colorectal Cancer Liver Metastases Resection
- 1Department of Clinical Science, Intervention and Technology, Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden
Abstract
Introduction: Treatment strategies for colorectal cancer liver metastases (CRLM) are increasingly complex, driving interest in advanced prognostic tools. Externally validated benchmarks based on established clinical risk scores are needed to contextualise emerging models. However, existing scores remain difficult to apply and compare, because they provide categorical risk strata rather than individualised probabilities, and because model parameters are rarely published. Here, we validate and recalibrate seven established risk scores to derive individualised recurrence probabilities for future score benchmarking. Method: Patients undergoing index CRLM resection from two tertiary centres were included: Karolinska University Hospital (retrospective KaroLiver cohort [2013-2021, follow-up to 2025, n=709]) and Oslo University Hospital (OSLO-COMET trial cohort [2012-2016, follow-up to 2022, n=198]). Performance of the GAME, m-CS, Fong, Nordlinger, Nagashima, Konopke and Helsinki scores was assessed using recurrence-free survival as the primary outcome. Results: Among 709 patients in KaroLiver (median age 67 years [IQR 59-74]; 434 men [61%]), 422 (60%) had synchronous metastases and 444 (63%) received neoadjuvant chemotherapy. All scores significantly stratified recurrence risk (log-rank P<0.001; time-dependent AUC 0.63-0.74 at 3 years), albeit with performance differences across time points. Recalibrated models showed good agreement between predicted and observed recurrence and were externally validated in OSLO-COMET with broadly comparable net benefit. Models were implemented in the online tool PLATO (Personalised Liver metastases risk AssessmenT in Oncology). Conclusion: Established CRLM risk scores can be translated into individualised probabilistic recurrence estimates at clinically relevant time points, supporting patient communication, risk-adapted surveillance and transparent benchmarking of next-generation prognostic models.
Related
- Three-dimensional multimodal fractal dynamics integrating spatial metabolism, cytoarchitecture, and perfusion for preoperative prediction of microvascular invasion in colorectal liver metastases
- Liver transplantation changes the rules for colorectal liver metastases
- Solitary bilateral adrenal metastases from colorectal cancer.
- Comparative efficacy of common adjuvant treatments after resection of colorectal liver metastases : A systematic review and network meta-analysis
- Advances in the Management of Colorectal Liver Metastases: 2026 SSAT–SSO Joint Expert Symposium at Digestive Disease Week
BibTeX
@misc{viljamaa2026individualised,
title = {{Individualised and Time-Dependent Prediction of Recurrence After Colorectal Cancer Liver Metastases Resection}},
author = {A. Viljamaa and R. Baumgartner and R. Strandberg and J. Sterner and S. Drejian and D. Aghayan and C. Fernandez Moro and E. Sparrelid and P. Osterlund and B. Edwin and A. A. Fretland and N. Geyer and J. Engstrand and M. Gerling},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.26367191},
url = {https://www.medrxiv.org/content/10.64898/2026.11.04.26367191v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Individualised and Time-Dependent Prediction of Recurrence After Colorectal Cancer Liver Metastases Resection
AU - A. Viljamaa
AU - R. Baumgartner
AU - R. Strandberg
AU - J. Sterner
AU - S. Drejian
AU - D. Aghayan
AU - C. Fernandez Moro
AU - E. Sparrelid
AU - P. Osterlund
AU - B. Edwin
AU - A. A. Fretland
AU - N. Geyer
AU - J. Engstrand
AU - M. Gerling
PY - 2026
DA - 2026/11/04
PB - medRxiv
DO - 10.64898/2026.11.04.26367191
UR - https://www.medrxiv.org/content/10.64898/2026.11.04.26367191v1
AB - Introduction: Treatment strategies for colorectal cancer liver metastases (CRLM) are increasingly complex, driving interest in advanced prognostic tools. Externally validated benchmarks based on established clinical risk scores are needed to contextualise emerging models. However, existing scores remain difficult to apply and compare, because they provide categorical risk strata rather than individualised probabilities, and because model parameters are rarely published. Here, we validate and recalibrate seven established risk scores to derive individualised recurrence probabilities for future score benchmarking. Method: Patients undergoing index CRLM resection from two tertiary centres were included: Karolinska University Hospital (retrospective KaroLiver cohort [2013-2021, follow-up to 2025, n=709]) and Oslo University Hospital (OSLO-COMET trial cohort [2012-2016, follow-up to 2022, n=198]). Performance of the GAME, m-CS, Fong, Nordlinger, Nagashima, Konopke and Helsinki scores was assessed using recurrence-free survival as the primary outcome. Results: Among 709 patients in KaroLiver (median age 67 years [IQR 59-74]; 434 men [61%]), 422 (60%) had synchronous metastases and 444 (63%) received neoadjuvant chemotherapy. All scores significantly stratified recurrence risk (log-rank P<0.001; time-dependent AUC 0.63-0.74 at 3 years), albeit with performance differences across time points. Recalibrated models showed good agreement between predicted and observed recurrence and were externally validated in OSLO-COMET with broadly comparable net benefit. Models were implemented in the online tool PLATO (Personalised Liver metastases risk AssessmenT in Oncology). Conclusion: Established CRLM risk scores can be translated into individualised probabilistic recurrence estimates at clinically relevant time points, supporting patient communication, risk-adapted surveillance and transparent benchmarking of next-generation prognostic models.
ER -